Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Dynamics Research

Executive Summary: Mdivi-1 (SKU A4472), provided by APExBIO, is a highly selective and cell-permeable inhibitor of mitochondrial division dynamin-related GTPase 1 (DRP1), essential for mitochondrial fission in eukaryotic cells (APExBIO). At 50 μM in vitro, Mdivi-1 blocks Drp1 self-assembly and mitochondrial division, reducing apoptosis as shown by annexin V staining (Qin et al., 2019). In vivo, 50 mg/kg intraperitoneal dosing preserves retinal ganglion cells without systemic side effects in mice. Mdivi-1 is insoluble in water and ethanol but dissolves in DMSO to ≥17.65 mg/mL; proper storage and warming protocols are required. Its validated applications include apoptosis assays, mitochondrial dynamics research, and neuroprotection in ischemic injury models.

Biological Rationale

Mitochondrial dynamics are regulated by fission and fusion events, which are critical for cellular homeostasis and apoptosis. DRP1, a large GTPase, is the primary mediator of mitochondrial fission in yeast and mammals. Dysregulated mitochondrial fission contributes to pathological conditions, including neurodegeneration, ischemic injury, and inflammatory disease (Qin et al., 2019). Selective inhibition of DRP1 allows researchers to dissect mitochondrial roles in apoptosis, disease modeling, and cellular metabolism. Mdivi-1 provides a tool for this selective inhibition, facilitating high-fidelity mitochondrial dynamics research (see review). This article extends prior overviews by integrating in vivo neuroprotection and apoptosis workflow data.

Mechanism of Action of Mdivi-1

Mdivi-1 binds selectively to the GTPase domain of DRP1 (also called dynamin I in yeast), inhibiting its GTP hydrolysis activity and thereby preventing Drp1 oligomerization and subsequent mitochondrial fission. This leads to elongated, interconnected mitochondrial networks in treated cells. Mechanistically, Mdivi-1 blocks Bid-activated Bax/Bak-dependent cytochrome c release from mitochondria, a pivotal step in the intrinsic, caspase-dependent and -independent apoptosis pathways. Inhibition of DRP1 also attenuates mitochondrial outer membrane permeabilization (MOMP), thereby reducing downstream cell death signals (contrast: strategic disruption article). Mdivi-1 does not directly inhibit fusion proteins such as OPA1 or MFN1/2, confirming its selectivity for the fission pathway.

Evidence & Benchmarks

• Mdivi-1 at 50 μM inhibits Drp1-mediated mitochondrial fission and self-assembly in vitro, resulting in decreased mitochondrial fragmentation in mammalian and yeast cells (Qin et al., 2019).
• In apoptosis assays, Mdivi-1 treatment reduces annexin V-positive cells compared to vehicle, demonstrating anti-apoptotic effects (Qin et al., 2019).
• Intraperitoneal administration of Mdivi-1 (50 mg/kg) in C57BL/6 mice after ischemic injury significantly increases retinal ganglion cell survival and reduces glial fibrillary acidic protein (GFAP) expression, indicating neuroprotection without affecting blood pressure or behavior (Qin et al., 2019).
• Mdivi-1 is insoluble in water and ethanol, but dissolves in DMSO at ≥17.65 mg/mL; recommended storage is as a solid at -20°C, with solutions stored below -20°C for several months (APExBIO).
• In models of pulmonary dysfunction, Mdivi-1 modulates the RIP1-RIP3-Drp1 pathway, reducing NLRP3 inflammasome activation via ER stress suppression (Qin et al., 2019).

Applications, Limits & Misconceptions

Applications:

• Apoptosis Assays: Mdivi-1 reduces Bax/Bak-mediated cytochrome c release, supporting its use in apoptosis quantification and mechanistic studies (see prior review; this article updates with new in vivo benchmarks).
• Mitochondrial Dynamics Research: Suitable for dissecting fission/fusion balance in cell biology, as it selectively targets DRP1 without affecting fusion proteins.
• Neuroprotection in Ischemic Retina: Demonstrated to increase RGC survival and reduce gliosis in mouse models of retinal ischemia, with no observed systemic toxicity (Qin et al., 2019).
• Pulmonary Dysfunction Models: Inhibits the NLRP3 inflammasome and ER stress responses in rat models of cough variant asthma (Qin et al., 2019).

Common Pitfalls or Misconceptions

• Mdivi-1 does not inhibit mitochondrial fusion proteins (e.g., MFN1/2, OPA1); it is selective for fission.
• Solubility is limited to DMSO; it is insoluble in water and ethanol, which can limit certain in vivo applications if not formulated properly.
• Long-term solution storage at >-20°C leads to degradation; always prepare fresh or store below -20°C for extended periods.
• Concentration-dependent off-target effects may occur at >100 μM; recommended working concentrations (10–50 μM in vitro) should not be exceeded.
• Mdivi-1's effects in non-mammalian species or plant mitochondria are not validated.

Workflow Integration & Parameters

Mdivi-1 (A4472) is supplied as a solid by APExBIO and should be stored at -20°C to maintain stability (product page). For experimental use, dissolve in DMSO to a stock concentration of ≥17.65 mg/mL. Warm to 37°C or use an ultrasonic bath for optimal dissolution. For in vitro assays, working concentrations are typically 10–50 μM, delivered directly to cell culture media. For in vivo models (e.g., neuroprotection in mice), intraperitoneal injection at 50 mg/kg is standard. Solutions are stable for several months at <-20°C, but avoid repeated freeze-thaw cycles. Integrate Mdivi-1 into apoptosis quantification, mitochondrial morphology assays, and neuroprotection protocols as a selective DRP1 inhibitor. For troubleshooting and advanced disease models, see this article, which this piece extends by adding ER stress and inflammasome modulation data.

Conclusion & Outlook

Mdivi-1 is a validated, selective inhibitor of DRP1-mediated mitochondrial fission, enabling precise studies of mitochondrial dynamics, apoptosis, and neuroprotective mechanisms across mammalian and yeast models. Its cell-permeability and specificity facilitate translational research in ischemic injury, neurodegeneration, and pulmonary dysfunction. Proper handling—especially regarding solubility, storage, and concentration—is essential for reproducibility. Ongoing research is expanding its utility in inflammatory and metabolic disease models, as highlighted by recent mechanistic data linking DRP1 to the NLRP3 inflammasome. For comprehensive application details and sourcing, consult the APExBIO Mdivi-1 product page.